---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047747"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:57:58.336242+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma doses first patient at UVA Cancer Center in Phase 2 glioblastoma trial of Ropidoxuridine

## Summary
- First patient enrolled and dosed at UVA Cancer Center; second site after Miami Cancer Institute.
- Phase 2 trial: 40 patients randomized to 1,200 or 960 mg/day to determine optimal dose, then add 14 more.
- Trial targets IDH wild-type, methylation negative glioblastoma; median survival <12 months with only radiation.
- Ropidoxuridine has FDA Orphan Drug Designation for glioblastoma.
- Six centers conducting trial: UVA, Georgetown, John Theurer, Allegheny Health, Miami Cancer Institute.

## SEC filing metadata
- accession: 0001493152-24-047747
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224047747/0001493152-24-047747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224047747/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047747
- JSON: https://secwatch.observer/filing/0001493152-24-047747.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.